Pregnancy induces major physiological, hormonal and biochemical changes to achieve an optimal outcome for the baby and its mother. When the pregnancy deviates from its normal course, there are many biochemical markers which can be used to assess these abnormalities. As biochemistry is only one part of obstetric care, results should be interpreted in conjunction with clinical and medical imaging data. Imaging is especially important and can be used to assess many placental and fetal abnormalities. Ultrasonography continues to improve and be refined in the early detection of fetal structural defects. It has equalled, if not superseded, biochemical testing in many aspects of obstetric care.
Introduction
Biochemical markers are used to assess maternal, placental and fetal health. They help to diagnose and monitor maternal conditions such as gestational diabetes and pre-eclampsia, trophoblastic disease and fetal chromosomal abnormalities such as Down's syndrome (Table 1) . These biochemical and hormonal tests constitute only one aspect of obstetric care.
They should be used together with clinical findings and imaging, particularly ultrasonography.
Biochemical assessment of maternal health
Common problems in pregnancy include gestational diabetes and pre-eclampsia.
Diabetes
The prevalence of gestational diabetes mellitus ranges from 1 to 14% depending on the populations studied. 1 In Australia, the prevalence ranges from 5.5 to 8.8%. 2 Screening for gestational diabetes mellitus in Australia is strongly advocated at 26-28 weeks of gestation. This enables early intervention which results in significant improvements in both fetal and maternal outcomes. 3 Occasionally, the serum glucose is unexpectedly found to be in the diabetic range in the first trimester. By definition, this is gestational diabetes mellitus, but does not distinguish between diabetes that may have preceded or occurred at the same time as pregnancy. The diagnosis can be confirmed by further tests of fasting glucose concentration or a 75 g oral glucose tolerance test. These patients should be reassessed in the postpartum period for evidence of diabetes. The woman's glycated haemoglobin (HbA1c) should be maintained in the normal range or as near normal as possible to ensure optimal fetal outcome.
Pre-eclampsia
Pre-eclampsia occurs typically in the third trimester and affects 4-8% of pregnancies. 4 It constitutes a triad of pregnancyassociated hypertension (that is, there is no pre-existing hypertension), marked proteinuria (greater than 300 mg daily) and pathological oedema. It is thus critical that urinary dipstick testing for protein, which can be fully quantitated if required, is performed at each antenatal visit together with blood pressure measurement and careful examination for oedema. Other findings include rises in serum uric acid (which can antedate the onset of hypertension), urea and creatinine. Low haemoglobin and platelet concentrations are informative if the patient is suspected to have the severe form of pre-eclampsiahaemolysis-elevated liver enzymes-low platelets (HELLP).
In the absence of pre-existing pathology, these biochemical parameters should return to normal after delivery.
Biochemical assessment of placental health
Ultrasonography has added another dimension to first trimester obstetric care to such an extent that many traditional biochemical tests have been rendered redundant. Maternal serum human placental lactogen and serum or urinary oestriol concentrations which were previously used extensively in the assessment of placental function, are rarely used nowadays.
Human chorionic gonadotrophin (HCG)
As pregnancy progresses, the patient's hormonal profile Physiologically, serum HCG arising from trophoblastic activity is elevated as early as the eighth day after implantation.
Concentrations double every 2-3 days and peak at approximately 10 weeks. They then decline and plateau out at a lower concentration until parturition (Fig. 1) .
In addition to confirming pregnancy, serum HCG can be used as a marker to assess various abnormalities in the first trimester. In these complex situations, ongoing communication with the laboratory is critical to the care and outcome for patients.
In the second trimester an elevated serum HCG concentration has been associated with a two-to threefold increased risk of fetal growth retardation. 7
Biochemical assessment of fetal health
The major aim of fetal assessment is to ensure satisfactory growth in utero. There are many factors which can cause fetal growth retardation. These range from poor maternal nutritional state to placental insufficiency and fetal abnormality. Similar to placental function, medical imaging is increasingly used to detect fetal abnormalities, thus reducing the utility of biochemical markers.
Alpha fetoprotein
Alpha fetoprotein is a fetal protein arising from the yolk sac and fetal liver. It can be detected in increasing concentrations in maternal serum until 32 weeks of normal gestation.
Neural tube defects
In neural tube defects such as spina bifida 8 
Down's syndrome
Down's syndrome is one of the common causes of fetal growth retardation. It is the result of either partial or total trisomy of chromosome 21 and is a major obstetric concern, particularly in older women. Important biochemical markers include alpha fetoprotein, HCG, unconjugated oestriol, pregnancy-associated plasma protein-A, serum inhibin-A and free β-HCG. These markers are used in various combinations and together with ultrasound to increase the detection rate of Down's syndrome.
It cannot be overemphasised that the gestational age must be correct in order for screening parameters to be accurate.
Between 11 and 13 weeks (that is late first trimester), serum
Fig.1 Human chorionic gonadotrophin (HCG) and thyroid stimulating hormone (TSH) concentrations
Note the broad reference intervals for HCG which peaks during the first trimester of pregnancy.
Represents the normal response of serum thyroid stimulating hormone (TSH) during pregnancy. The reference range (RR) for TSH is in the shaded area. Note the drop in TSH concentration in the first trimester corresponding with the peak HCG concentration. This is due to negative feedback on TSH secretion resulting from the stimulating effect of HCG on TSH receptors.
The high baseline HCG concentration with markedly shortened doubling time suggests multiple pregnancy or a trophoblastic tumour.
Failure of HCG to rise or double with time. This suggests the presence of an unviable or ectopic pregnancy or threatened miscarriage. 
Other approaches
Another biochemical method of assessing fetal health is the analysis of amniotic fluid. The measurement of bilirubin concentration in amniotic fluid is critical for assessing fetal intravascular haemolysis in the presence of Rhesus incompatability. The lecithin-to-sphingomyelin ratio in amniotic fluid can be used to assess fetal lung maturity in preterm labour but is rarely used these days due to the widespread availability of synthetic surfactant.
Recently, there has been a resurgence of interest using maternal growth hormone and insulin-like growth factor levels during the first and second trimester of pregnancy as predictors of fetal outcome, but these are yet to be of routine clinical use. 12 
Fetal DNA
A major advance in molecular biology has been the possible detection and isolation of fetal DNA in the maternal circulation. 13 This exciting discovery has opened up new horizons in the 'non-invasive' assessment of fetal-maternal health. Any dentists who carry a blood-borne virus have a professional and ethical responsibility to review the way they practise so as to ensure that they minimise the likelihood of infecting their patients. The Australian Dental Association offers advice and co-operation that should be sought.
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Managing hepatitis C in the community (p.36)
The number of Australian adults living with hepatitis C is increasing and is not confined to any one section of the population. Dentists need to be aware that hepatitis C may be present in the saliva of infected patients. Our infection control practices therefore need to be exemplary to avoid spread of ■ EpiPen will now be produced with Australian packaging by Dey Laboratories to save on repacking time in Australia ■ CSL will work with wholesalers and pharmacies to minimise the time stock spends on shelves
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